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The Clinical Pharmacogenomics Service (CPS) at Boston
Children’s Hospital (BCH) was established to use geno-
mic information to make pediatric medications safer.
Nearly one-quarter of outpatients are prescribed one or
more drugs with genetic information in the FDA label
[1]. However, there are still important barriers that must
be overcome for routine pharmacogenomic (PGx) clini-
cal use: (1) identification of clinically significant variants,
(2) knowledge of variant genotype prior to prescribing
medication, and (3) integration with current electronic
health record (EHR) systems. To tackle these challenges
at BCH, the CPS decided to standardize thiopurine
S-methyltransferase (TPMT) testing hospital-wide.
TPMT is best known for its role in the catalyzing the
S-methylation of the thiopurine drugs such as azathiopr-
ine, 6-mercaptopurine and 6-thioguanine. Approximately
13% of Caucasians and African Americans are heterozy-
gous and have reduced TPMT activity, while approxi-
mately 0.3% are completely deficient. Defects in the
TPMT gene can lead to decreased methylation and exces-
sive levels of the toxic thioguanine nucleotides, particularly
with azathioprine and 6-mercaptopurine, and are at risk
for bone marrow suppression.
Although the FDA drug label recommends testing for
TPMT deficiency prior to dosing and the PharmGKB
CPIC group published a guideline [2] with a recom-
mended dosing strategy and interpretation, testing is not
universal because these guidelines are difficult to translate
into a clinical decision support (CDS) system and integrate
with the EHRs. We developed models and specifications to
execute PGx CDS rules based on a patient’s genotype.
Rules are modeled at four levels of abstraction: (1)
unstructured (narrative), (2) semi-structured, (3) struc-
tured, and (4) executable.
As genomic sequencing becomes routine, standardized
methods to interpret the data and make clinical decisions
are paramount. In conjunction with the BCH DNA Diag-
nostic Laboratory, we streamlined the TPMT testing pro-
cess to fit into the usual clinical routine (including
ordering, testing in-house and return of results to the
clinician). We consolidated all genetic sequencing testing
into a single clinical workflow (blood to report) that is
run, analyzed and interpreted in a Clinical Laboratory
Improvement Amendments (CLIA) certified laboratory
using the codified CDS rules. The interpretation reports
are generated automatically directly from the genotype
calls and then manually reviewed for accuracy. Once
cleared by the laboratory director, the reports are
uploaded into the EHR (Cerner). Specialty flow sheets
enable providers to easily view the allele status and inter-
pretation report. We intend to expand the PGx platform
to include additional drug/gene pairs.
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